Alimentary pharmacology & therapeutics

publication venue for

Comparison of clinical prediction rules for ruling out cirrhosis in nonalcoholic fatty liver disease (NAFLD).. 55. 2022
Ustekinumab is effective and safe for ulcerative colitis through 2 years of maintenance therapy.. 52. 2020
Comparative safety and effectiveness of vedolizumab to tumour necrosis factor antagonist therapy for Crohn's disease.. 52. 2020
Impact of a digital medicine programme on hepatitis C treatment adherence and efficacy in adults at high risk for non-adherence.. 51. 2020
Reported proton pump inhibitor side effects: what are physician and patient perspectives and behaviour patterns?. 51. 2019
Endoscopic activity in asymptomatic patients with an ileal pouch is associated with an increased risk of pouchitis.. 50. 2019
Disability in inflammatory bowel disease patients is associated with race, ethnicity and socio-economic factors.. 49. 2019
Effectiveness, treatment completion and safety of sofosbuvir/ledipasvir and paritaprevir/ritonavir/ombitasvir + dasabuvir in patients with chronic kidney disease: an ERCHIVES study.. 48. 2018
Regional gastrointestinal contractility parameters using the wireless motility capsule: inter-observer reproducibility and influence of age, gender and study country.. 47. 2017
Hepatitis B reactivation and outcomes in persons treated with directly acting antiviral agents against hepatitis C virus: results from ERCHIVES.. 47. 2017
Proton pump inhibitors are associated with accelerated development of cirrhosis, hepatic decompensation and hepatocellular carcinoma in noncirrhotic patients with chronic hepatitis C infection: results from ERCHIVES.. 47. 2017
The albumin-bilirubin grade uncovers the prognostic relationship between hepatic reserve and immune dysfunction in HIV-associated hepatocellular carcinoma.. 47. 2017
The PAC-SYM questionnaire for chronic constipation: defining the minimal important difference.. 46. 2017
Factors associated with villus atrophy in symptomatic coeliac disease patients on a gluten-free diet.. 45. 2017
Do directly acting antiviral agents for HCV increase the risk of hepatic decompensation and decline in renal function? Results from ERCHIVES.. 45. 2016
All-oral direct-acting antiviral therapy in HCV-advanced liver disease is effective in real-world practice: observations through HCV-TARGET database.. 45. 2016
Body mass index greater than 35 is associated with severe Clostridium difficile infection.. 45. 2016
Adding ribavirin to newer DAA regimens does not affect SVR rates in HCV genotype 1 infected persons: results from ERCHIVES.. 44. 2016
Regional gastrointestinal transit and pH studied in 215 healthy volunteers using the wireless motility capsule: influence of age, gender, study country and testing protocol.. 42. 2015
Clinical and demographic characteristics predictive of treatment outcomes for certolizumab pegol in moderate to severe Crohn's disease: analyses from the 7-year PRECiSE 3 study.. 42. 2015
Randomised clinical trial: daily pantoprazole magnesium 40 mg vs. esomeprazole 40 mg for gastro-oesophageal reflux disease, assessed by endoscopy and symptoms.. 39. 2013
Randomised clinical trials: linaclotide phase 3 studies in IBS-C - a prespecified further analysis based on European Medicines Agency-specified endpoints.. 37. 2012
Randomised clinical trial: rifaximin improves health-related quality of life in cirrhotic patients with hepatic encephalopathy - a double-blind placebo-controlled study.. 34. 2011
The incidence, predictors and management of anaemia and its association with virological response in HCV / HIV coinfected persons treated with long-term pegylated interferon alfa 2a and ribavirin.. 33. 2011
Altered peripheral toll-like receptor responses in the irritable bowel syndrome.. 33. 2011
Randomised clinical trial: ghrelin agonist TZP-101 relieves gastroparesis associated with severe nausea and vomiting--randomised clinical study subset data.. 33. 2011
Randomised clinical trial: a novel rabeprazole extended release 50 mg formulation vs. esomeprazole 40 mg in healing of moderate-to-severe erosive oesophagitis - the results of two double-blind studies.. 33. 2010
Measuring symptoms in the irritable bowel syndrome: development of a framework for clinical trials.. 32. 2010
Prevalence, knowledge and care patterns for gastro-oesophageal reflux disease in United States minority populations.. 32. 2010
Characterizing abdominal pain in IBS: guidance for study inclusion criteria, outcome measurement and clinical practice.. 32. 2010
A model of healing of Los Angeles grades C and D reflux oesophagitis: is there an optimal time of acid suppression for maximal healing?. 32. 2010
Drug treatment of chronic-intermittent abdominal cramping and pain: a multi-national survey on usage and attitudes.. 32. 2010
Clinical trial: gastric acid suppression in Hispanic adults with symptomatic gastro-oesophageal reflux disease - comparator study of esomeprazole, lansoprazole and pantoprazole.. 32. 2010
The safety of intravenous fluorescein for confocal laser endomicroscopy in the gastrointestinal tract.. 31. 2009
Measuring irritable bowel syndrome patient-reported outcomes with an abdominal pain numeric rating scale.. 30. 2009
Clinical trial: the efficacy, impact on quality of life, and safety and tolerability of prucalopride in severe chronic constipation--a 12-week, randomized, double-blind, placebo-controlled study.. 29. 2008
Clinical trial: dextofisopam in the treatment of patients with diarrhoea-predominant or alternating irritable bowel syndrome.. 27. 2007
Relationship between intragastric acid control and healing status in the treatment of moderate to severe erosive oesophagitis.. 25. 2007
Comparison of the effects of immediate-release omeprazole oral suspension, delayed-release lansoprazole capsules and delayed-release esomeprazole capsules on nocturnal gastric acidity after bedtime dosing in patients with night-time GERD symptoms.. 25. 2007
Rates and predictors of hepatitis C virus treatment in HCV-HIV-coinfected subjects.. 24. 2006
Prevalence and management of abdominal cramping and pain: a multinational survey.. 24. 2006
Placebo- and paracetamol-controlled study on the efficacy and tolerability of hyoscine butylbromide in the treatment of patients with recurrent crampy abdominal pain.. 23. 2006
Introduction: the scientific and clinical rationale for extended acid suppression.. 23 Suppl 2. 2006
Intragastric acid suppression and pharmacokinetics of twice-daily esomeprazole: a randomized, three-way crossover study.. 20. 2004
The acidity index: a simple approach to the measurement of gastric acidity.. 19. 2004
Esomeprazole resolves chronic heartburn in patients without erosive oesophagitis.. 18. 2003
The prophylactic use of a proton pump inhibitor before food and alcohol.. 17. 2003
Baclofen decreases acid and non-acid post-prandial gastro-oesophageal reflux measured by combined multichannel intraluminal impedance and pH.. 17. 2003
Effect of oral omeprazole in reducing re-bleeding in bleeding peptic ulcers: a prospective, double-blind, randomized, clinical trial.. 17. 2003
Dose-dependent control of intragastric pH by pantoprazole, 10, 20 or 40 mg, in healthy volunteers.. 16. 2002
Over-the-counter H(2)-receptor antagonists do not compromise intragastric pH control with proton pump inhibitors.. 16. 2002
Bedtime H2 blockers improve nocturnal gastric acid control in GERD patients on proton pump inhibitors.. 15. 2001
Control of intragastric pH with omeprazole 20 mg, omeprazole 40 mg and lansoprazole 30 mg.. 15. 2001
Maximal acid reflux control for Barrett's oesophagus: feasible and effective.. 15. 2001
The effects of tegaserod (HTF 919) on oesophageal acid exposure in gastro-oesophageal reflux disease.. 14. 2000
Proton pump inhibitors: better acid suppression when taken before a meal than without a meal.. 14. 2000
Gastric acidity and acid breakthrough with twice-daily omeprazole or lansoprazole.. 14. 2000
Oesophageal motility defects associated with nocturnal gastro-oesophageal reflux on proton pump inhibitors.. 13. 1999
Post-prandial ranitidine is superior to post-prandial omeprazole in control of gastric acidity in healthy volunteers.. 13. 1999
Bedtime ranitidine does not eliminate the need for a second daily dose of omeprazole to suppress nocturnal gastric pH.. 13. 1999
Gastro-oesophageal reflux associated with nocturnal gastric acid breakthrough on proton pump inhibitors.. 12. 1998
Nocturnal gastric acidity and acid breakthrough on different regimens of omeprazole 40 mg daily.. 12. 1998
Transdermal delivery of erythromycin lactobionate--implications for the therapy of gastroparesis.. 11. 1997
Effects of psyllium therapy on stool characteristics, colon transit and anorectal function in chronic idiopathic constipation.. 9. 1995
Comparative effects of intraduodenal psyllium and senna on canine small bowel motility.. 8. 1994
Commentary: faecal microbiota transplantation-from home brew to holy grail. 2020
Commentary: daily pantoprazole vs. esomeprazole for GERD--authors' reply. 2014
Commentary: biopsy to diagnose GERD--better, but not yet a stand-alone test. 2013
Commentary: synbiotics and gut microbiota in older people--a microbial guide to healthy ageing. 2013
Commentary: revisiting the past--does it hold the key to the future treatment of refractory GERD? 2013
Commentary: psychoeducation in the irritable bowel syndrome--talking the talk. 2013
Commentary: long-term lubiprostone for constipation predominant IBS. 2012
Letter: fighting the battle but losing the war-inflammatory bowel disease and venous thromboembolism. 2022
Letter: non-invasive prediction models to exclude cirrhosis in NAFLD-not everyone fits the mould. Authors' reply. 2022
Letter: bone fracture risk among older long-term users of proton pump inhibitors. Authors' reply. 2020
Letter: meta-analysis of prebiotics, probiotics, synbiotics and antibiotics in IBS. Authors' reply. 2019
Letter: complex interplay between obesity and Clostridium difficile infection-authors' reply. 2017
Letter: low muscle mass and disordered eating as causes of osteopenia in inflammatory bowel disease. 2015
Commentary: Probing probiotics in cirrhosis--a template for future studies? 2014
Commentary: irritable bowel syndrome and the CDAI--misleading activity by straw men. 2013
Bifidobacterium bifidum MIMBb75 in irritable bowel syndrome. 2011
Eosinophilic oesophagitis in noncardiac chest pain. 2011
Adipokines and gastrointestinal disease. 2006
Nocturnal gastric acid breakthrough on proton pump inhibitors. 1999
Clinical role of ambulatory reflux monitoring in PPI non-responders: recommendation statements. 2022
Editorial: refractory reflux sensitivity - a place for baclofen?. 56. 2022
Editorial: non-erosive reflux disease is often not GERD-time to change the definition or abandon the term?. 54. 2021
Editorial: simultaneous prolonged monitoring of the acid pocket and oesophageal reflux.. 52. 2020
Editorial: moving towards appropriate use of proton pump inhibitors. Authors' reply.. 51. 2020
Editorial: Lactobacillus GG for diarrhoea in children-reports of its demise have been premature!. 49. 2019
Editorial: refractory GERD-good drug, wrong patients?. 46. 2017
Editorial: risk factors for persistent villus atrophy in coeliac disease - is it time to reconsider definitions for refractory coeliac disease? Authors' reply.. 45. 2017
Editorial: are earlier referrals to transplant centres responsible for improved outcomes in patients with acute liver failure?. 45. 2017
Editorial: balancing fibre and FODMAPs in IBS - a 'rye' look at an old problem.. 44. 2016
Editorial: serotonin and irritable bowel syndrome--reconciling pharmacological effects with basic biology.. 43. 2016
Editorial: do we have a new addition to our GERD treatment tool box?. 43. 2016
Editorial: anti-secretory therapy prior to anti-reflux surgery. Does dose matter?. 42. 2015
Editorial: differentiating chronic idiopathic constipation from constipation-predominant irritable bowel syndrome--possible and important?. 41. 2015
Editorial: allergy and recurrent abdominal pain of childhood/irritable bowel syndrome.. 41. 2015
Systematic review with meta-analysis: the prevalence of coeliac disease in patients with osteoporosis. 2018
Systematic review with meta-analysis: proximal disease extension in limited ulcerative colitis. 2017
Conducting multinational, cross-cultural research in the functional gastrointestinal disorders: issues and recommendations. A Rome Foundation working team report. 2014
Review article: the endocannabinoid system in liver disease, a potential therapeutic target. 2014
Review article: current treatment options and management of functional dyspepsia. 2012
Systematic review: cardiovascular safety profile of 5-HT(4) agonists developed for gastrointestinal disorders. 2012
Review article: probiotics for the treatment of irritable bowel syndrome--focus on lactic acid bacteria. 2012
Review article: a pharmacoeconomic analysis of thrombocytopenia in chronic liver disease. 2007
Review article: the pathophysiology of thrombocytopenia in hepatitis C virus infection and chronic liver disease. 2007
Review article: the role of antibiotics vs. conventional pharmacotherapy in treating symptoms of irritable bowel syndrome. 2007
Review article: acid-related disease--what are the unmet clinical needs? 2006
Review article: from gastrin to gastro-oesophageal reflux disease--a century of acid suppression. 2006
Review article: intragastric and oesophageal pH monitoring in patients with gastro-oesophageal reflux disease. 2006
Systematic review: Complementary and alternative medicine in the irritable bowel syndrome. 2006
Review article: putting immediate-release proton-pump inhibitors into clinical practice--improving nocturnal acid control and avoiding the possible complications of excessive acid exposure. 2005
Review article: quality-of-life issues in gastro-oesophageal reflux disease. 2005
Review article: supra-oesophageal manifestations of gastro-oesophageal reflux disease and the role of night-time gastro-oesophageal reflux. 2004
Review article: gastric emptying in functional gastrointestinal disorders. 2004
New developments in the pathophysiology of gastro-oesophageal reflux disease (GERD): implications for patient management. 2003
Review article: the role of non-acid reflux in gastro-oesophageal reflux disease. 2000

VIVO Weill Cornell Medical College

Alimentary pharmacology & therapeutics Journal

Overview

publication venue for

Identity

ISO Abbreviation

Linking ISSN

International Standard Serial Number (ISSN)

Electronic International Standard Serial Number (EISSN)